Kevin Marsh
University of Oxford
H-index: 152
Europe-United Kingdom
Description
Kevin Marsh, With an exceptional h-index of 152 and a recent h-index of 66 (since 2020), a distinguished researcher at University of Oxford, specializes in the field of malaria, global health, tropical medicine.
His recent articles reflect a diverse array of research interests and contributions to the field:
Patients’ Preferences for Systemic Lupus Erythematosus Treatments—A Discrete Choice Experiment
Development of WHO recommendations for the final phase of elimination and prevention of re-establishment of malaria
Using Patient Preferences in Health Technology Assessment: Evaluating Quality-Adjusted Survival Equivalents (QASE) for the Quantification of Non-health Benefits
Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease
HTA296 Applying Continual Stakeholder Engagement to Develop Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Major Depressive Disorder (MDD)
Funding and COVID-19 research in Africa: two years on, ar e the research needs of Africa being met?[version 1; peer
Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
Abstract P335: Patient Preferences For Renal Denervation In Uncontrolled Hypertension: The RADIANCE PREFER Study
Professor Information
University | University of Oxford |
---|---|
Position | ___ |
Citations(all) | 78346 |
Citations(since 2020) | 19060 |
Cited By | 67860 |
hIndex(all) | 152 |
hIndex(since 2020) | 66 |
i10Index(all) | 521 |
i10Index(since 2020) | 345 |
University Profile Page | University of Oxford |
Research & Interests List
malaria
global health
tropical medicine
Top articles of Kevin Marsh
Patients’ Preferences for Systemic Lupus Erythematosus Treatments—A Discrete Choice Experiment
BackgroundSymptoms of systemic lupus erythematosus (SLE) vary between patients, but those of increased disease activity typically include musculoskeletal and mucocutaneous manifestations such as joint pain, swelling, and rashes. Several treatment options are available to patients with SLE with variable efficacy. Many treatments, especially corticosteroids, cause unwanted side effects, although little is currently known about patients’ preferences for treatments of SLE.ObjectiveWe aimed to identify which attributes of SLE treatment are valued by patients and to quantify their relative importance.MethodsAdult participants with moderate-to-severe SLE were asked to make a series of choices between two hypothetical treatments in an online discrete choice experiment (DCE). A latent class model (LCL) was estimated to analyze choice data. Relative attribute importance (RAI) was calculated to determine the …
Authors
Hannah Collacott,Andrea Phillips-Beyer,Nicolas Krucien,Bruno Flamion,Kevin Marsh
Journal
The Patient-Patient-Centered Outcomes Research
Published Date
2024/1/25
Development of WHO recommendations for the final phase of elimination and prevention of re-establishment of malaria
The WHO recommends that all affected countries work toward the elimination of malaria, even those still experiencing a high burden of disease. However, malaria programs in the final phase of elimination or those working to prevent re-establishment of transmission after elimination could benefit from specific evidence-based recommendations for these settings as part of comprehensive and quality-controlled malaria guidelines. The WHO convened an external guideline development group to formulate recommendations for interventions to reduce or prevent malaria transmission in areas with very low–to low-transmission levels and those that have eliminated malaria. In addition, several interventions that could be deployed in higher burden areas to accelerate elimination, such as mass drug administration, were reviewed. Systematic reviews were conducted that synthesized and evaluated evidence for the benefits …
Authors
Kevin Marsh,Elie Akl,Jane Achan,Mohammed Alzahrani,J Kevin Baird,Teun Bousema,Dionicia Gamboa,Marcus Lacerda,Kamini Mendis,Melissa Penny,Allan Schapira,Siv Sovannaroth,Chansuda Wongsrichanalai,Amanda Tiffany,Xiaohong Li,Erin Shutes,David Schellenberg,Pedro Alonso,Kim A Lindblade,WHO Malaria Elimination Steering Group
Journal
The American Journal of Tropical Medicine and Hygiene
Published Date
2024/4
Using Patient Preferences in Health Technology Assessment: Evaluating Quality-Adjusted Survival Equivalents (QASE) for the Quantification of Non-health Benefits
Interest in using patient preference (PP) data alongside traditional economic models in health technology assessment (HTA) is growing, including using PP data to quantify non-health benefits. However, this is limited by a lack of standardised methods. In this article, we describe a method for using discrete choice experiment (DCE) data to estimate the value of non-health benefits in terms of quality-adjusted survival equivalence (QASE), which is consistent with the concept of value prevalent among HTA agencies. We describe how PP data can be used to estimate QASE, assess the ability to test the face-validity of QASE estimates of changes in mode of administration calculated from five published DCE oncology studies and review the methodological and normative considerations associated with using QASE to support HTA. We conclude that QASE may have some methodological advantages over alternative …
Authors
Kevin Marsh,Hannah Collacott,Jim Thomson,Jonathan Mauer,Stephen Watt,Koonal Shah,Brett Hauber,Louis Garrison,Mendwas Dzingina
Journal
The Patient-Patient-Centered Outcomes Research
Published Date
2024/2/29
Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease
IntroductionInformation about patient preferences for the treatment of anaemia associated with chronic kidney disease (CKD) is scarce. Hence, our aim was to examine how patients with non-dialysis-dependent CKD valued attributes of alternative hypothetical anaemia treatments.MethodsA discrete choice experiment (DCE) was conducted in adult patients who reported a clinical diagnosis of CKD-related anaemia. Treatment attributes included mode and frequency of administration, need for iron supplementation, risk of gastrointestinal side effects, risk of major cardiovascular events and impact on energy levels (as defined by the vitality section of the SF-6D health index). Logit models were used to analyse patients’ preferences.ResultsThe DCE was completed by 200 patients in four countries. Patients preferred an oral mode of administration. Patients were willing to tolerate a 5.1% (95% CI 2.0–8.3%) increase in …
Authors
Ana Filipa Alexandre,Antonia Morga,Caitlin Thomas,Nicolas Krucien,Tommi Tervonen,Alina Jiletcovici,Kevin Marsh
Journal
Advances in Therapy
Published Date
2023/2
HTA296 Applying Continual Stakeholder Engagement to Develop Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Major Depressive Disorder (MDD)
ObjectivesEngagement with decision-makers is crucial to the development of decision tools in health technology assessment. This study applied a continual stakeholder engagement approach to develop an open-source multi-criteria decision analysis (MCDA) to support decision-making in major depressive disorder (MDD) by diverse stakeholders in the US.MethodsThe MCDA was developed based on the 8-step process in ISPOR Good Practices Reports. We convened a twenty-member advisory group (AG) consisting of representatives from patient, clinician, employer, payer, manufacturer, and researcher perspectives throughout the process to ensure the module can effectively address real-world decision needs. Facilitated discussions were conducted to define decision problems, prioritize criteria, and identify performance metrics for different criteria. Three MCDA experts provided guidance to identify the best …
Authors
R Chapman,R Xie,YYM Cheng,CE Phelps,K Marsh,P Thokala
Journal
Value in Health
Published Date
2023/12/1
Funding and COVID-19 research in Africa: two years on, ar e the research needs of Africa being met?[version 1; peer
Background The Coronavirus disease 2019 (COVID-19) pandemic caused significantly lower reported mortalities on the African continent as compared to other regions. Yet, many countries on the continent are still contending with the devastating economic, social and indirect health impacts. African researchers and policy makers have identified research priority areas which take cognisance of the unique research needs of African countries. A baseline assessment of the alignment of funded research in Africa to these priorities and World Health Organization’s COVID-19 research priorities was undertaken in July, 2020. We present a two-year update to this analysis of funded COVID-19 research in Africa. Methods Data captured in the UK Collaborative on Development Research and Global Research Collaboration for Infectious Disease Preparedness COVID-19 Research Project Tracker as of 15th July, 2022 was analysed. An additional analysis of institutions receiving funding for COVID-19 research is presented. We also analysed the change in funding for COVID-19 research in Africa since July, 2020. Results The limited COVID-19 research identified in Africa early in the pandemic has persisted over the subsequent two-year period assessed. When number of projects are considered, governmental funders based in Europe and United States supported the most research. Only nine research funders based in Africa were identified. A number of partnerships between African institutions and institutions based on other continents were identified, however, most research projects were undertaken in research institutions based in Africa only. Our …
Authors
Emilia Antonio,Moses Alobo,Marta Tufet Bayona,Kevin Marsh,Proochista Ariana,Alice Norton
Published Date
2023
Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS, S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short …
Authors
Muzamil Mahdi Abdel Hamid,Mohamed Hassan Abdelraheem,Desmond Omane Acheampong,Ambroise Ahouidi,Mozam Ali,Jacob Almagro-Garcia,Alfred Amambua-Ngwa,Chanaki Amaratunga,Lucas Amenga-Etego,Ben Andagalu,Tim Anderson,Voahangy Andrianaranjaka,Ifeyinwa Aniebo,Enoch Aninagyei,Felix Ansah,Patrick O Ansah,Tobias Apinjoh,Paulo Arnaldo,Elizabeth Ashley,Sarah Auburn,Gordon A Awandare,Hampate Ba,Vito Baraka,Alyssa Barry,Philip Bejon,Gwladys I Bertin,Maciej F Boni,Steffen Borrmann,Teun Bousema,Marielle Bouyou-Akotet,Oralee Branch,Peter C Bull,Huch Cheah,Keobouphaphone Chindavongsa,Thanat Chookajorn,Kesinee Chotivanich,Antoine Claessens,David J Conway,Vladimir Corredor,Erin Courtier,Alister Craig,Umberto d'Alessandro,Souleymane Dama,Nicholas Day,Brigitte Denis,Mehul Dhorda,Mahamadou Diakite,Abdoulaye Djimde,Christiane Dolecek,Arjen Dondorp,Seydou Doumbia,Chris Drakeley,Eleanor Drury,Patrick Duffy,Diego F Echeverry,Thomas G Egwang,Sonia Maria Mauricio Enosse,Berhanu Erko,Rick M Fairhurst,Abdul Faiz,Caterina A Fanello,Mark Fleharty,Matthew Forbes,Mark Fukuda,Dionicia Gamboa,Anita Ghansah,Lemu Golassa,Sonia Goncalves,GL Abby Harrison,Sara Anne Healy,Jason A Hendry,Anastasia Hernandez-Koutoucheva,Tran Tinh Hien,Catherine A Hill,Francis Hombhanje,Amanda Hott,Ye Htut,Mazza Hussein,Mallika Imwong,Deus Ishengoma,Scott A Jackson,Chris G Jacob,Julia Jeans,Kimberly J Johnson,Claire Kamaliddin,Edwin Kamau,Jon Keatley,Theerarat Kochakarn,Drissa S Konate,Abibatou Konaté,Aminatou Kone,Dominic P Kwiatkowski,Myat P Kyaw,Dennis Kyle,Mara Lawniczak,Samuel K Lee,Martha Lemnge,Pharath Lim,Chanthap Lon,Kovana M Loua,Celine I Mandara,Jutta Marfurt,Kevin Marsh,Richard James Maude,Mayfong Mayxay,Oumou Maïga-Ascofaré,Olivo Miotto,Toshihiro Mita,Victor Mobegi,Abdelrahim Osman Mohamed,Olugbenga A Mokuolu,Jaqui Montgomery,Collins Misita Morang’a,Ivo Mueller,Kathryn Murie,Paul N Newton,Thang Ngo Duc,Thuy Nguyen,Thuy-Nhien Nguyen,Tuyen Nguyen Thi Kim,Hong Nguyen Van,Harald Noedl,Francois Nosten,Rintis Noviyanti,Vincent Ntui-Njock Ntui,Alexis Nzila,Lynette Isabella Ochola-Oyier,Harold Ocholla,Abraham Oduro,Irene Omedo,Marie A Onyamboko,Jean-Bosco Ouedraogo,Kolapo Oyebola,Wellington Aghoghovwia Oyibo,Richard Pearson,Norbert Peshu,Aung P Phyo,Christopher V Plowe,Ric N Price,Sasithon Pukrittayakamee,Huynh Hong Quang,Milijaona Randrianarivelojosia,Julian C Rayner,Pascal Ringwald,Anna Rosanas-Urgell,Eduard Rovira-Vallbona,Valentin Ruano-Rubio,Lastenia Ruiz,David Saunders,Alex Shayo
Journal
Wellcome open research
Published Date
2023
Abstract P335: Patient Preferences For Renal Denervation In Uncontrolled Hypertension: The RADIANCE PREFER Study
Objective: Blood pressure control is a challenge for patients for reasons including adherence, medication side effects, poor access to healthcare, and inconvenience of long-term treatment. Renal denervation is a treatment option that lowers blood pressure in combination with lifestyle modifications and medications, but it requires a minimally invasive procedure. This study assessed how patients make choices between treatments, and quantified their willingness to undergo renal denervation. Methods: An online discrete choice experiment (DCE) was completed by US adults with uncontrolled hypertension despite being prescribed ≥1 medication. In 10 DCE tasks, participants chose between two hypothetical treatments defined by the 10-year cardiovascular (CV) risk, current treatments (procedure/number of pills per day), durability/need for future treatments (additional procedure or pills), and risks of mild-to …
Authors
Naomi D Fisher,Roland E Schmieder,Jaein Seo,Dimitri A Augustin,Leslie A Coleman,Helen Reeve-Stoffer,Myrto Trapali,Kevin Marsh
Journal
Hypertension
Published Date
2023/9
Professor FAQs
What is Kevin Marsh's h-index at University of Oxford?
The h-index of Kevin Marsh has been 66 since 2020 and 152 in total.
What are Kevin Marsh's top articles?
The articles with the titles of
Patients’ Preferences for Systemic Lupus Erythematosus Treatments—A Discrete Choice Experiment
Development of WHO recommendations for the final phase of elimination and prevention of re-establishment of malaria
Using Patient Preferences in Health Technology Assessment: Evaluating Quality-Adjusted Survival Equivalents (QASE) for the Quantification of Non-health Benefits
Preferences for Anaemia Treatment Attributes among Patients with Non-Dialysis-Dependent Chronic Kidney Disease
HTA296 Applying Continual Stakeholder Engagement to Develop Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Major Depressive Disorder (MDD)
Funding and COVID-19 research in Africa: two years on, ar e the research needs of Africa being met?[version 1; peer
Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
Abstract P335: Patient Preferences For Renal Denervation In Uncontrolled Hypertension: The RADIANCE PREFER Study
...
are the top articles of Kevin Marsh at University of Oxford.
What are Kevin Marsh's research interests?
The research interests of Kevin Marsh are: malaria, global health, tropical medicine
What is Kevin Marsh's total number of citations?
Kevin Marsh has 78,346 citations in total.